Please use this identifier to cite or link to this item:
http://hdl.handle.net/10553/42990
Title: | Tricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential CB<inf>2</inf>receptor ligands with antagonist/inverse agonist properties | Authors: | Deiana, Valeria Gómez-Cañas, María Pazos, M. Ruth Fernández-Ruiz, Javier Asproni, Battistina Cichero, Elena Fossa, Paola Muñoz, Eduardo Deligia, Francesco Murineddu, Gabriele García-Arencibia, Moisés Pinna, Gerard A. |
UNESCO Clasification: | 32 Ciencias médicas | Keywords: | CB(2) antagonism Cannabinoid receptors Molecular modelling Synthesis Tricyclic pyrazoles |
Issue Date: | 2016 | Publisher: | 0223-5234 | Journal: | European Journal of Medicinal Chemistry | Abstract: | Previous studies have investigated the relevance and structure-activity relationships (SARs) of pyrazole derivatives in relation with cannabinoid receptors, and the series of tricyclic 1,4-dihydroindeno[1,2-c]pyrazoles emerged as potent CB2 receptor ligands. In the present study, novel 1,4-dihydroindeno[1,2-c]pyrazole and 1H-benzo[g]indazole carboxamides containing a cyclopropyl or a cyclohexyl substituent were designed and synthesized to evaluate the influence of these structural modifications towards CB1 and CB2 receptor affinities. Among these derivatives, compound 15 (6-cyclopropyl-1-(2,4-dichlorophenyl)-N-(adamantan-1-yl)-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide) showed the highest CB2 receptor affinity (Ki = 4 nM) and remarkable selectivity (KiCB1/KiCB2 = 2232), whereas a similar affinity, within the nM range, was seen for the fenchyl derivative (compound 10: Ki = 6 nM), for the bornyl analogue (compound 14: Ki = 38 nM) and, to a lesser extent, for the aminopiperidine derivative (compound 6: Ki = 69 nM). Compounds 10 and 14 were also highly selective for the CB2 receptor (KiCB1/KiCB2 > 1000), whereas compound 6 was relatively selective (KiCB1/KiCB2 = 27). The four compounds were also subjected to GTPγS binding analysis showing antagonist/inverse agonist properties (IC50 for compound 14 = 27 nM, for 15 = 51 nM, for 10 = 80 nM and for 6 = 294 nM), and this activity was confirmed for the three more active compounds in a CB2 receptor-specific in vitro bioassay consisting in the quantification of prostaglandin E2 release by LPS-stimulated BV2 cells, in the presence and absence of WIN55,212-2 and/or the investigated compounds. Modelling studies were also conducted with the four compounds, which conformed with the structural requirements stated for the binding of antagonist compounds to the human CB2 receptor. | URI: | http://hdl.handle.net/10553/42990 | ISSN: | 0223-5234 | DOI: | 10.1016/j.ejmech.2016.02.005 | Source: | European Journal of Medicinal Chemistry [ISSN 0223-5234], v. 112, p. 66-80 |
Appears in Collections: | Artículos |
SCOPUSTM
Citations
21
checked on Nov 24, 2024
WEB OF SCIENCETM
Citations
20
checked on Nov 24, 2024
Page view(s)
18
checked on Jul 8, 2023
Google ScholarTM
Check
Altmetric
Share
Export metadata
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.